A non-P-glycoprotem-mediated mechanism of multidrug resistance (non-Pgp MDR) has been identified in doxorubicin-selected sublines of the human non-sma cell lung carinoma cell line SW-1573. These sublines are cross-resistant to daunorubicin, VP16-213, Vinca alkaloids, colchicine, gramIcidin D, and 4'-(9-acrkdlylamino)methansulfon-m-anidlde
erase H gene expression was not. We conclude that the MDR phenotype, the reduced drug accumulation, and the loss of MDR] P-glycoprotein mRNA are genetically linked. They might be due to a single dominant mutation, which does not cause the alteration in topoisomerase II.
Cells selected for resistance to a natural, cytotoxic product may become cross-resistant to a series of large, hydrophobic, cytotoxic drugs that do not share a common structure or target (1, 2) . Such multidrug-resistant (MDR) cells usually contain increased levels of P-glycoprotein, a membrane protein that can act as a drug efflux pump, actively lowering the intracellular drug concentration (3) (4) (5) (6) (7) . Not all MDR cell lines contain increased levels ofP-glycoprotein, however. Some of these lines are. only resistant to drugs that interact with topoisomerase 11 (8) (9) (10) (11) . These lines contain either an altered topoisomerase II (10, 11) or a decreased level of topoisomerase II (8, 9) . Other cell lines have been described, however, that are resistant to many of the drugs extruded by P-glycoprotein even though they do not detectably overexpress P-glycoprotein (12) (13) (14) (15) (16) (17) (18) (19) . The molecular basis of resistance in these non-P-glycoprotein-mediated MDR (non-Pgp MDR) cell lines has not been identified.
Clinical studies to date have failed to indicate a consistent correlation between the level of MDR] P-glycoprotein with nonresponse to chemotherapy in some of the major human cancers, such as lung and breast cancer (20, 21) . Therefore elucidation of the molecular basis of non-Pgp MDR should provide the tools to test whether this form of drug resistance can account for therapy failure in these tumors.
To clarify the mechanism of such a form of non-Pgp MDR we have studied three resistant cell lines, independently derived from the human non-small cell lung cancer cell line SW-1573 (12, 22, 23) . These lines, obtained by doxorubicin selection, are resistant to a wide range of MDR drugs (Table  1 and ref. 12 ) and they have a decreased accumulation Of daunorubicin, vincristine (24) , and VP16-213 (06). Both cannot be reversed by verapamil. Another remarkable feature of these lines is the loss of the MJJRJ P-glycoprotein mRNA, whereas this is readily detectable in the parental SW-1573 cells (12) . Transcripts of the other human P-glycoprotein gene, the MDR3 gene (3), are not detectable either in the parental cell line or in the non-Pgp MDR cell lines (12) . A contribution of the MDR] and MDR3 P-glycoproteins to the resistance of the non-Pgp MDR cell lines is therefore excluded.
To investigate whether the entire phenotype of these cell lines is due to a single, dominant mutation, we have tested here whether it could be transferred by somatic cell fusion from lethally y-irradiated, resistant donor cells to drugsensitive parental acceptor cells.
MATERIALS AND METHODS
Cell Culture. Doxorubicin-resistant cell lines were derived from the human non-small cell lung cancer cell line SW-1573 and were isolated as described (12, 22, 23) . The non-Pgp MDR cell lines iR50b and 2R50 were isolated from the drug-sensitive cell line S1 by a multistep doxorubicin selection up to 50 nM, whereas cell line 3R80 was isolated by a single step at 80 nM doxorubicin and was subcloned, resulting in cell line 3R8. In the selection procedure the iR50b and 2R50 cell lines were cloned once, and karyotypic analysis of these lines shows that they are homogeneous (A.W.M.N., unpublished data). For the cell fusion experiments the cell lines were recloned. As acceptor, a subclone of the drugsensitive parental cell line S1 transfected with pSV2a3.6 (25) , which encodes the a-1 subunit of the mouse sodium/ potassium exchanger, conferring >1000-fold resistance to ouabain, was used, Slou. As donor, we used a subclone of the non-Pgp MDR cell line iR50b transfected with pCDneo (26) , conferring resistance to G-418 sulfate, lRSObneo. For Abbreviations: MDR, multidrug resistance; non-Pgp MDR, non-Pglycoprotein-mediated mechanism of MDR.
tTo whom reprint requests should be addressed. §Present address: Department of Genetics, University of Groningen, 9751 NN Haren, The Netherlands.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
selection of these clones, 1 ,uM ouabain or 0.8 mg of G-418 per ml was used. The transfected, subcloned cell lines showed the same sensitivity to other cytotoxic drugs as their nontransfected parents. All cells were free of Mycoplasma as tested by the use of the Gen-Probe rapid Mycoplasma detection system (Gen-Probe, San Diego).
Assay of Drug Resistance. The clonogenic survival assay was carried out as described by Baas et al. (12) . The relative resistance was calculated as the ratio of IC1o (inhibitory concentration where 10% of the cells survive) of the resistant cell line to the IC10 of the parental cell line.
Topoisomerase II Catalytic Activity. Nuclear extracts were isolated as described by Pommier et al. (11) . The catalytic activity of topoisomerase II was measured in a decatenation assay (27, 28) . The decatenation of kinetoplast DNA (29) In all experiments a probe for y-actin (34) was included to measure RNA recovery. The intensity of the topoisomerase II and y-actin mRNA bands in each sample was determined by scanning the autoradiographs with a Beckmann DU-8 scanning system; topoisomerase II mRNA levels were corrected for the amount of y-actin mRNA.
Somatic Cell Fusion. The procedure for the somatic cell fusion experiments is shown in Fig. 1 . lR50bneo cells were lethally y-irradiated with a dose of 15 Gy [with two '37Cs sources of 415 Ci each (1 Ci = 37 GBq), Von Gahlen Nederland B.V., Didam, The Netherlands]. Slou cells (0.7 x 106) and y-irradiated lR50bneo cells (3.3 X 106) were mixed, spun down, resuspended in Ham's F-10 culture medium, and plated on a 100-mm culture dish (Falcon 3003, Becton Dickinson). When the cells were attached to the tissue culture dish, they were fused using 2 ml of polyethylene glycol 1500 (PEG 1500; 783641 Boehringer Mannheim, according to the manufacturer's suggested conditions). The following day the cell population was trypsinized and 1/15th was reseeded per 150-mm tissue culture dish (Falcon 3025, Becton Dickinson). The next day one part of the cell population was selected with 1 /.M ouabain and 800 Ag of G-418 per ml for the first 5 days, followed by selection with 400 Ag of G-418 per ml. The other part of the cell population was selected for the first 5 days with 1 ,M ouabain and with one of the following drugs: vincristine (12 nM), doxorubicin (50 nM), or VP16-213 (100 nM). After 5 days the ouabain selection was stopped, and vincristine or doxorubicin selection continued at the same level whereas VP16-213 selection was reduced to 50 nM. Drug-resistant colonies were isolated after 2 weeks of selection.
Cellular Drug Accumulation. Steady-state accumulation of drugs was measured according to Broxterman et al. (35 In view of the high resistance of the non-Pgp MDR cell lines to drugs known to interact with topoisomerase II (see Table  1 ), we investigated whether topoisomerase II activity was decreased or altered in the non-Pgp MDR cell lines by decatenation of kinetoplast DNA in nuclear extracts. At equal protein concentrations, nuclear extracts from the nonPgp MDR cell lines lR50b and 2R50 contained less decatenating activity than the nuclear extracts derived from the parental cell line (Table 2) . This difference was present in logarithmic phase and in confluent cells. The topoisomerase II activities of the cell lines lRSOb, 2R50, and S1 were equally sensitive to VP16-213 (data not shown), indicating that the lowered topoisomerase II of the non-Pgp MDR cell lines was functionally equivalent to topoisomerase II of the drugsensitive parental cell line.
The reduction of topoisomerase II activity was accompanied by a reduction in topoisomerase II protein (immunoblot not shown). RNase protection experiments using an antisense topoisomerase II cDNA probe showed that the nonPgp MDR cell lines (lR50b, 2R50, and 3R8) contained reduced topoisomerase II mRNA levels as well (Fig. 2) . This decrease was found in logarithmic phase and in confluent cells ( Table 2 ). The Pgp-overproducing cell line 1R500-0, derived from iR50b by prolonged doxorubicin selection (23) , also showed the decrease in topoisomerase II mRNA, whereas this was not present in cell line S1 1.1, which overproduces Pgp upon transfection of MDR] cDNA (Fig. 2) . Table 3 show that the ,--irradiated lR50bneo cells did not survive at all and that the parental Slou acceptor cells did not survive in the presence of G418. After fusion of Slou cells to -irradiated lR50bneo cells, however, cells resistant to G418 and ouabain were obtained (see Table 3 ), indicating that the fusions were successful.
To test for transfer ofthe non-Pgp MDR phenotype, similar experiments were performed in which doxorubicin, VP16-213, or vincristine each in combination with ouabain was used for selection after the cell fusion. The only cells that can be expected to grow under these selection conditions are Slou cells that have received the mutation conferring the non-Pgp MDR from the lRSObneo cells or in which MDR has been induced by the fusion procedure. The experiments summarized in Table 3 for vincristine/ouabain selection show that the frequency of drug-resistant cells obtained by PEG 1500 fusion is at least 15 times higher when a non-Pgp MDR donor cell is used instead of a drug-sensitive S1 donor cell. In these experiments no colonies appeared on tissue culture dishes containing the -t-irradiated lR50bneo alone, and only zero to two colonies appeared on dishes containing tThe number of independent fusion experiments was 2; per fusion experiment three dishes were analyzed at the selection conditions indicated.
The fused cells accumulated less daunorubicin and vincristine than the drug-sensitive parental cell line (see Table 4 for cell line F6. 1-F6.4). The accumulation defect of the fused cells for vincristine, however, was smaller than that of the non-Pgp MDR donor cell line lRSObneo, although they had a higher resistance level (Table 1) . We attribute this discrepancy (in part) to the larger volume and thus the increased amount of binding sites for vincristine of the fused cells compared to the lRSObneo donor cells. In a Coulter Counter calibrated with microbeads, the average volume of the fused cells was about 50% larger than that of the donor cells.
To examine whether the alterations in MDR] and topoisomerase II gene expression are cotransferred with drug resistance from the lRSObneo donor cells to the sensitive parental cells, the MDR] and topoisomerase II mRNA levels were determined in the MDR fused cells. As shown in Fig. 3 , five of the seven fused cell clones analyzed (F6.1-F6.4 and F10.12.3) have no detectable MDRI P-glycoprotein mRNA, whereas MDR] P-glycoprotein mRNA is readily detectable in the drug-sensitive parental cell line S1. Thus, in these clones, the decrease of MDR] P-glycoprotein mRNA level is cotransferred with resistance to the parental cell line in these somatic cell hybrids. In contrast, all fused cells have topoisomerase II expression levels identical to the parental cell line S1 (Fig. 2) , showing that down-regulation of topoisomerase II gene expression is not transferred in the somatic cell fusion. Two of the seven fused cell lines (F10.10.1 and F10.10.2) had an increased level of MDR] P-glycoprotein expression relative to the parental cell line (Fig. 3) . These were the cell lines with the high vincristine resistance (Table   1) .
DISCUSSION
In this paper we show that part of the non-Pgp MDR phenotype in our SW-1573 cells can be transferred to a sensitive recipient cell line in somatic cell fusion experiments. This indicates that the genetic alteration responsible for resistance acts in a dominant fashion. Therefore, it may be possible to identify the mutated gene by transfection of sensitive cells with DNA from resistant cells.
We have previously shown that the non-Pgp MDR cell lines accumulate less drug (24) 2R160 (12, 22, 23) .
We show here that the expression of the topoisomerase II gene in the non-Pgp MDR cell lines is also decreased com-pared to the parental cell line. This decrease does not cotransfer with the modified non-Pgp MDR phenotype to the drug-sensitive cells in somatic cell fusion experiments. This suggests that the non-Pgp MDR phenotype of the cell lines is due to at least two independent genetic alterations. One of these alterations causes authentic non-Pgp MDR characterized by reduced drug accumulation with a concomitant low-level resistance to various MDR drugs and the loss of MDR] P-glycoprotein mRNA; the other alteration reduces the level of topoisomerase II gene expression. The reduced topoisomerase II may contribute to the resistant phenotype of the non-Pgp MDR lines, such as 1RSOb, for the topoisomerase II drugs doxorubicin, VP16-213, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) since these cell lines are more resistant to these drugs than the fused cells that lack the topoisomerase II alteration.
The presence of two unlinked genetic alterations in all three independent mutants selected for low-level resistance is unexpected. This is not due to genetic heterogeneity, as shown by extensive subcloning. It is possible that the frequency of mutations or stable epigenetic alterations resulting in topoisomerase II decrease is high but that this decrease by itself is insufficient for a 5-fold resistance to doxorubicin, the resistance level for which the cells were initially selected. If this interpretation is correct, it should be possible to select SW-1573 mutants with either decreased topoisomerase II alone or non-Pgp MDR mutants alone by using low concentrations of the appropriate drugs (see Table 1 ).
The increased resistance to non-topoisomerase II drugs in the fused cells may be due to selection. To completely kill sensitive cells we were forced to select for resistance with 12 nM vincristine, a concentration that already affects the iR50b cell line used as fusion donor (see Table 1 ). We may therefore have selected for increased expression (e.g., by amplification) of the genetic change responsible for non-Pgp MDR. The high level of selection required in the somatic cell fusion experiments might also be the reason for the generation of hybrids with a moderate level of P-glycoprotein expression (F10.10.1 and F10.10.2) after somatic cell fusion. Since prolonged drug selection of the non-Pgp MDR cell lines resulted in MDR] overproducing cell lines (12, 22, 23) , we might also have selected for P-glycoprotein expression in a subset of the non-Pgp MDR hybrids by the stringent selection. Whether these cell lines also contain the non-Pgp MDR remains to be investigated.
Several other cell lines with a non-Pgp type of MDR have been described in recent years (12) (13) (14) (15) (16) (17) (18) (19) . Most of these lines were selected for high degrees of resistance by many rounds of selection. Given our results, it seems likely that resistance in these cell lines is due to several additive mutations as well. The somatic cell fusion method used here to dissect a compound resistant genotype may also be of use for the further characterization of these other cell lines.
